FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Chris Tyrrell

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Physiology

Disease Progression

Procedures

Co-author Network

Publications

TOP 3
M Wirth; Chris J Tyrrell; Karl P J Delaere; M Sánchez-Chapado; J Ramon; D M A Wallace; J Hetherington; F Pina; C F Heyns; S Navani; Jon Armstrong
Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up.
Chris J Tyrrell; Peter Iversen; Teuvo Tammela; John Anderson; Thomas Björk; Amir V Kaisary; Tom Morris
Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
William A See; Chris J Tyrrell
The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Chris Tyrrell (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: M Wirth; Chris J Tyrrell; Karl P J Delaere; M Sánchez-Chapado; J Ramon; D M A Wallace; J Hetherington; F Pina; C F Heyns; S Navani; Jon Armstrong
Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up.
Prostate cancer and prostatic diseases 2007;10(1):87-93.
2006: Chris J Tyrrell; Peter Iversen; Teuvo Tammela; John Anderson; Thomas Björk; Amir V Kaisary; Tom Morris
Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
BJU international 2006;98(3):563-72.
2006: William A See; Chris J Tyrrell
The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
Journal of cancer research and clinical oncology 2006;132 Suppl 1():S7-16.
2005: Chris J Tyrrell; Heather Payne; William A See; David G McLeod; Manfred P Wirth; Peter Iversen; Jon Armstrong; Clive Morris
Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2005;76(1):4-10.
2005: Hein Van Poppel; Chris J Tyrrell; Karin Haustermans; P Van Cangh; F Keuppens; P Colombeau; Tom Morris; L Garside
Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer.
European urology 2005;47(5):587-92.
2005: M Wirth; Chris J Tyrrell; Karl P J Delaere; M Sánchez-Chapado; J Ramon; D M A Wallace; J Hetherington; F Pina; C Heyns; T Borchers; Tom Morris; Jon Armstrong
Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme.
Prostate cancer and prostatic diseases 2005;8(2):194-200.
2004: Chris J Tyrrell; Heather Payne; Teuvo L J Tammela; August Bakke; Pär Lodding; Louis Goedhals; Peter Van Erps; Tom Boon; Cees Van De Beek; Swen-Olof Andersson; Tom Morris; Kevin Carroll
Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia.
International journal of radiation oncology, biology, physics 2004;60(2):476-83.
2004: Peter Iversen; Manfred P Wirth; William A See; David G McLeod; Ira W Klimberg; Donald Gleason; Gerald Chodak; James E Montie; Chris J Tyrrell; D M A Wallace; Karl P J Delaere; Per Lundmo; Teuvo L J Tammela; Jan-Erik Johansson; Tom Morris; Kevin Carroll
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.
Urology 2004;63(5):928-33.
2003: Chris J Tyrrell; G M Blake; Peter Iversen; Amir V Kaisary; I Melezinek
The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study.
World journal of urology 2003;21(1):37-42.
2002: William A See; Manfred P Wirth; David G McLeod; Peter Iversen; Ira W Klimberg; Donald Gleason; Gerald Chodak; James E Montie; Chris J Tyrrell; D M A Wallace; Karl P J Delaere; Sigmund Vaage; Teuvo L J Tammela; Olavi Lukkarinen; Bo-Eric Persson; Kevin Carroll; Geert J C M Kolvenbag
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
The Journal of urology 2002;168(2):429-35.
2001: M Wirth; Chris J Tyrrell; M Wallace; Karl P J Delaere; M Sánchez-Chapado; J Ramon; J Hetherington; F Pina; C F Heynes; T M Borchers; Tom Morris; A Stone
Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.
Urology 2001;58(2):146-51.
2000: Peter Iversen; Chris J Tyrrell; Amir V Kaisary; JB Anderson; Hein Van Poppel; Teuvo L J Tammela; M Chamberlain; Kevin Carroll; I Melezinek
Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
The Journal of urology 2000;164(5):1579-82.
2000: Chris J Tyrrell; J E Altwein; F Klippel; C Jurincic-Winkler; E Varenhorst; G Lunglmayr; F Boccardo; I M Holdaway; J M Haefliger; J P Jordaan
Comparison of an LH-RH analogue (Goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group.
European urology 2000;37(2):205-11.
1999: Chris J Tyrrell
Adjuvant and neoadjuvant hormonal therapy for prostate cancer.
European urology 1999;36(6):549-58.
1999: Chris J Tyrrell
Controversies in the management of advanced prostate cancer.
British journal of cancer 1999;79(1):146-55.
1998: F J Debruyne; R Murray; Y Fradet; Jan-Erik Johansson; Chris J Tyrrell; F Boccardo; L Denis; J M Marberger; D Brune; J Rassweiler; T Vangeneugden; J Bruynseels; M Janssens; P de Porre
Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group.
Urology 1998;52(1):72-81.
1998: Peter Iversen; Chris J Tyrrell; Amir V Kaisary; JB Anderson; L Baert; Teuvo Tammela; M Chamberlain; Kevin Carroll; K Gotting-Smith; George Blackledge
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
Urology 1998;51(3):389-96.
1998: Chris J Tyrrell; Amir V Kaisary; Peter Iversen; JB Anderson; L Baert; Teuvo Tammela; M Chamberlain; A Webster; George Blackledge
A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.
European urology 1998;33(5):447-56.
1998: Chris J Tyrrell; LJ Denis; Donald W W Newling; Mark S Soloway; K Channer; I D Cockshott
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.
European urology 1998;33(1):39-53.
1995: Amir V Kaisary; Chris J Tyrrell; C Beacock; G Lunglmayr; F Debruyne
A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group.
European urology 1995;28(3):215-22.
1995: C J Williams; V L Barley; George Blackledge; C G Rowland; Chris J Tyrrell; F Bachelot; A Dermaille; P Fargeot; M Namer; J Pouillart
Multicentre cross-over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer.
Clinical oncology (Royal College of Radiologists (Great Britain)) 1995;7(2):87-92.
1993: Chris J Tyrrell; J E Altwein; F Klippel; E Varenhorst; G Lunglmayr; F Boccardo; I M Holdaway; J M Haefliger; J P Jordaan; M Sotarauta
Multicenter randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. International Prostate Cancer Study Group.
Cancer 1993;72(12 Suppl):3878-9.
1993: C J Williams; V L Barley; George Blackledge; C G Rowland; Chris J Tyrrell
Multicentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer.
British journal of cancer 1993;68(6):1210-5.
1992: Chris J Tyrrell
Casodex: a pure non-steroidal anti-androgen used as monotherapy in advanced prostate cancer.
The Prostate. Supplement 1992;4():97-104.
1991: Chris J Tyrrell; J E Altwein; F Klippel; E Varenhorst; G Lunglmayr; F Boccardo; I M Holdaway; J M Haefliger; J P Jordaan
A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
The Journal of urology 1991;146(5):1321-6.
1991: Amir V Kaisary; Chris J Tyrrell; W B Peeling; K Griffiths
Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.
British journal of urology 1991;67(5):502-8.
1989: M G Wyatt; T J Clarke; Chris J Tyrrell; J C Hammonds
Cystic prostatic carcinoma.
British journal of urology 1989;64(4):430-1.
1988: N S Stuart; Michael H Cullen; T J Priestman; George Blackledge; Chris J Tyrrell
A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
Cancer chemotherapy and pharmacology 1988;21(4):351-4.
1986: H Stevens; P Hickling; Chris J Tyrrell; J C Hammonds
Reiter's syndrome after radiotherapy for prostatic carcinoma.
British journal of rheumatology 1986;25(4):417-8.